Factors associated with a strictly undetectable viral load in HIV-1-infected patients

HIV Med. 2012 Oct;13(9):568-73. doi: 10.1111/j.1468-1293.2012.01012.x. Epub 2012 Mar 21.

Abstract

Objectives: The aim of the study was to identify factors associated with a strictly undetectable viral load (VL) using a routine sensitive real-time polymerase chain reaction (RT-PCR) technology.

Methods: From a large prospective cohort, 1392 patients with a VL<50 HIV-1 RNA copies/mL while receiving a three-drug suppressive regimen for at least 1 year were included in a cross-sectional analysis. Patients were classified into three groups and compared by univariate and multivariate analysis: 479 patients with a strictly undetectable VL (group 1; 34%), 617 patients with detectable VL below the threshold of 20 copies/mL (group 2; 44%), and 296 patients with a VL of 20-50 copies/mL (group 3; 12%).

Results: Comparing groups 1 and 2, VL zenith<5 log(10) copies/mL [odds ratio (OR) 1.51; 95% confidence interval (CI) 1.15-1.99; P=0.003], current CD4 T-cell count<500 cells/μL (OR 1.44; 95% CI 1.08-1.92; P=0.01), and duration of viral suppression<50 copies/mL longer than 2 years (OR 2.32; 95% CI 1.20-4.54; P=0.01) were associated with undetectable VL. Comparing groups 1 and 3, VL zenith<5 log(10) copies/mL (OR 2.48; 95% CI 1.75-3.50; P<0.001), duration of viral suppression<50 copies/mL longer than 1 year (OR 3.33; 95% CI 1.66-6.66; P=0.0006), and nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens (OR 1.45; 95% CI 1.03-2.04; P=0.03) were associated with undetectable VL. No individual drug effect was found within NNRTI molecules.

Conclusions: Longer duration of viral suppression<50 copies/mL, lower viral load zenith and NNRTI-based regimen were independently associated with a strictly undetectable viral load. This routinely used RT-PCR assay may prove to be a valuable tool in further large-scale studies.

MeSH terms

  • Anti-HIV Agents / administration & dosage*
  • CD4 Lymphocyte Count
  • Cross-Sectional Studies
  • Drug Therapy, Combination
  • Female
  • HIV Seropositivity / blood*
  • HIV Seropositivity / drug therapy
  • HIV Seropositivity / genetics
  • HIV-1 / genetics
  • HIV-1 / metabolism*
  • Humans
  • Male
  • Prospective Studies
  • Real-Time Polymerase Chain Reaction
  • Risk Factors
  • Viral Load*

Substances

  • Anti-HIV Agents